Redefining Bronchiectasis Research and Management With First FDA Approval

In the concluding portion of the HCPLive RX Review Special Report, Albert Rizzo, MD, and James Chalmers, MBChB, PhD, discuss how the August 2025 FDA approval of brensocatib (marketed as Brinsupri), the first disease modifying therapy for bronchiectasis, may shift therapeutic goals in the field beyond exacerbation reduction and toward long-term preservation of pulmonary health.